FY2030 Earnings Forecast for CNTB Issued By HC Wainwright

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – HC Wainwright issued their FY2030 earnings per share estimates for shares of Connect Biopharma in a report issued on Monday, January 26th. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.11) per share for the year. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share.

Connect Biopharma (NASDAQ:CNTB) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.07).

CNTB has been the topic of several other research reports. Wall Street Zen upgraded shares of Connect Biopharma to a “hold” rating in a research report on Saturday, December 20th. Lake Street Capital began coverage on Connect Biopharma in a research note on Monday, December 1st. They issued a “buy” rating and a $9.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Connect Biopharma in a research note on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Connect Biopharma in a report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Connect Biopharma Trading Up 1.9%

Shares of Connect Biopharma stock opened at $2.65 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.48 and a quick ratio of 5.48. Connect Biopharma has a 1 year low of $0.51 and a 1 year high of $3.28. The firm has a market cap of $148.15 million, a PE ratio of -3.63 and a beta of -0.19. The company has a 50 day simple moving average of $2.53 and a two-hundred day simple moving average of $2.06.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of Connect Biopharma in the second quarter valued at about $29,000. AlphaCore Capital LLC acquired a new position in shares of Connect Biopharma in the second quarter valued at $78,000. Finally, Koa Wealth Management LLC bought a new position in Connect Biopharma in the second quarter worth $49,000. Institutional investors and hedge funds own 58.72% of the company’s stock.

Connect Biopharma Company Profile

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.